NCT07053059View on ClinicalTrials.gov

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2030

Conditions
Acute Lymphocytic Leukemia (ALL)
Interventions
DRUG

Obecabtagene autoleucel

given by Infusion

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Autolus, Ltd

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT07053059 - Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) | Biotech Hunter | Biotech Hunter